Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy

  • Seung Tae Kim1,
  • Jeeyun Lee1,
  • Se Hoon Park1,
  • Joon Oh Park1,
  • Young Suk Park1,
  • Won Ki Kang1 and
  • Ho Yeong Lim1Email author
BMC Cancer201717:211

https://doi.org/10.1186/s12885-017-3196-6

Received: 5 April 2016

Accepted: 14 March 2017

Published: 23 March 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
5 Apr 2016 Submitted Original manuscript
1 Dec 2016 Reviewed Reviewer Report - Todd Miller
27 Dec 2016 Author responded Author comments - Seung Kim
Resubmission - Version 2
27 Dec 2016 Submitted Manuscript version 2
29 Jan 2017 Author responded Author comments - Seung Kim
Resubmission - Version 3
29 Jan 2017 Submitted Manuscript version 3
4 Mar 2017 Author responded Author comments - Seung Kim
Resubmission - Version 4
4 Mar 2017 Submitted Manuscript version 4
Publishing
14 Mar 2017 Editorially accepted
23 Mar 2017 Article published 10.1186/s12885-017-3196-6

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Advertisement